Why did the FDA delay its decision on AstraZeneca’s camizestrant?

The FDA postponed its ruling on AstraZeneca’s oral SERD camizestrant after an advisory committee voted six to three that the drug lacked a clinically meaningful benefit. AstraZeneca has since submitted new biomarker analyses, including ctDNA data, which regulators will review before setting a new decision date amid broader oncology review delays.